secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2023-06-20T23:59:59+00:00
Accession:  0001140361-23-030499
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Eterna Therapeutics shareholders approve all four proposals at 2023 annual meeting
--------------------------------------------------------------------------------

- Elected five directors: Cherington, Angel, Fiore, Wexler, Singer — each received >2.68M votes for, ~770K broker non-votes.
- Ratified Grant Thornton as auditor for FY 2023: 3.52M for, 23K against, 6K abstain.
- Approved potential issuance of >20% of outstanding shares under Lincoln Park Capital purchase agreement: 2.75M for, 27K against.
- Approved amendment to Restated 2020 Stock Incentive Plan, increasing reserved shares from 680,599 to 980,599: 2.62M for, 160K against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036123030499/0001140361-23-030499-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036123030499/brhc20054589_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-030499

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer